Literature DB >> 25238882

Minithoracotomy for mitral valve repair improves inpatient and postdischarge economic savings.

Eugene A Grossi1, Scott Goldman2, J Alan Wolfe3, John Mehall4, J Michael Smith5, Gorav Ailawadi6, Arash Salemi7, Matt Moore8, Alison Ward9, Candace Gunnarsson10.   

Abstract

OBJECTIVE: Small series of thoracotomy for mitral valve repair have demonstrated clinical benefit. This multi-institutional administrative database analysis compares outcomes of thoracotomy and sternotomy approaches for mitral repair.
METHODS: The Premier database was queried from 2007 to 2011 for mitral repair hospitalizations. Premier contains billing, cost, and coding data from more than 600 US hospitals, totaling 25 million discharges. Thoracotomy and sternotomy approaches were identified through expert rules; robotics were excluded. Propensity matching on baseline characteristics was performed. Regression analysis of surgical approach on outcomes and costs was modeled.
RESULTS: Expert rule analysis positively identified thoracotomy in 847 and sternotomy in 566. Propensity matching created 2 groups of 367. Mortalities were similar (thoracotomy 1.1% vs sternotomy 1.9%). Sepsis and other infections were significantly lower with thoracotomy (1.1% vs 4.4%). After adjustment for hospital differences, thoracotomy carried a 17.2% lower hospitalization cost (-$8289) with a 2-day stay reduction. Readmission rates were significantly lower with thoracotomy (26.2% vs 35.7% at 30 days and 31.6% vs 44.1% at 90 days). Thoracotomy was more common in southern and northeastern hospitals (63% vs 37% and 64% vs 36%, respectively), teaching hospitals (64% vs 36%) and larger hospitals (>600 beds, 78% vs 22%).
CONCLUSIONS: Relative to sternotomy, thoracotomy for mitral repairs provides similar mortality, less morbidity, fewer infections, shorter stay, and significant cost savings during primary admission. The markedly lower readmission rates for thoracotomy will translate into additional institutional cost savings when a penalty on hospitals begins under the Affordable Care Act's Hospital Readmissions Reduction Program.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25238882     DOI: 10.1016/j.jtcvs.2014.08.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Cost effectiveness of robotic mitral valve surgery.

Authors:  Emmanuel Moss; Michael E Halkos
Journal:  Ann Cardiothorac Surg       Date:  2017-01

2.  Is minimally invasive thoracoscopic surgery the new benchmark for treating mitral valve disease?

Authors:  Andrew B Goldstone; Y Joseph Woo
Journal:  Ann Cardiothorac Surg       Date:  2016-11

Review 3.  Minimally invasive mitral valve surgery.

Authors:  Yasir Abu-Omar; Ibrahim T Fazmin; Jason M Ali; Marc P Pelletier
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

4.  Minimally invasive versus conventional sternotomy for Mitral valve repair: protocol for a multicentre randomised controlled trial (UK Mini Mitral).

Authors:  Rebecca H Maier; Adetayo S Kasim; Joseph Zacharias; Luke Vale; Richard Graham; Antony Walker; Grzegorz Laskawski; Ranjit Deshpande; Andrew Goodwin; Simon Kendall; Gavin J Murphy; Vipin Zamvar; Renzo Pessotto; Clinton Lloyd; Malcolm Dalrymple-Hay; Roberto Casula; Hunaid A Vohra; Franco Ciulli; Massimo Caputo; Serban Stoica; Max Baghai; Gunaratnam Niranjan; Prakash P Punjabi; Olaf Wendler; Leanne Marsay; Cristina Fernandez-Garcia; Paul Modi; Bilal H Kirmani; Mark D Pullan; Andrew D Muir; Dimitrios Pousios; Helen C Hancock; Enoch Akowuah
Journal:  BMJ Open       Date:  2021-04-14       Impact factor: 2.692

5.  Upper Hemi-Sternotomy Provides Benefit for Patients with Isolated or Combined Mitral Valve Surgery.

Authors:  Cenk Ulvi Oezpeker; Fabian Barbieri; Daniel Hoefer; Nikolaos Bonaros; Michael Grimm; Ludwig Mueller
Journal:  Medicina (Kaunas)       Date:  2022-01-18       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.